{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "epsTrailingTwelveMonths": -1.03, "epsForward": -0.95, "epsCurrentYear": -0.9, "priceEpsCurrentYear": -4.1000004, "sharesOutstanding": 25269900, "bookValue": 0.467, "fiftyDayAverage": 3.91514, "fiftyDayAverageChange": -0.22513986, "fiftyDayAverageChangePercent": -0.057504933, "twoHundredDayAverage": 4.45219, "twoHundredDayAverageChange": -0.76218987, "twoHundredDayAverageChangePercent": -0.17119437, "marketCap": 98845136, "forwardPE": -3.8842106, "priceToBook": 7.901499, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "currency": "EUR", "financialCurrency": "USD", "regularMarketOpen": 3.69, "averageDailyVolume3Month": 36, "averageDailyVolume10Day": 15, "fiftyTwoWeekLowChange": 0.96500015, "fiftyTwoWeekLowChangePercent": 0.3541285, "fiftyTwoWeekRange": "2.725 - 6.624", "fiftyTwoWeekHighChange": -2.934, "fiftyTwoWeekHighChangePercent": -0.44293478, "fiftyTwoWeekLow": 2.725, "fiftyTwoWeekHigh": 6.624, "earningsTimestamp": 1683837000, "earningsTimestampStart": 1691524800, "earningsTimestampEnd": 1692043200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "firstTradeDateMilliseconds": 1323327600000, "priceHint": 4, "marketState": "REGULAR", "regularMarketChange": 0.025000095, "regularMarketTime": 1683875702, "regularMarketDayHigh": 3.69, "regularMarketDayRange": "3.69 - 3.69", "regularMarketDayLow": 3.69, "regularMarketVolume": 150, "regularMarketPreviousClose": 3.665, "bid": 3.7, "ask": 3.84, "fullExchangeName": "Frankfurt", "regularMarketChangePercent": 0.6821309, "regularMarketPrice": 3.69, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "exchange": "FRA", "shortName": "CAPRICOR THERAP.  DL-,001", "longName": "Capricor Therapeutics, Inc.", "messageBoardId": "finmb_29535381", "market": "dr_market", "symbol": "4LN2.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "10865 Road to the Cure", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "(858) 727-1755", "website": "https://www.capricor.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.", "fullTimeEmployees": 74, "companyOfficers": [{"maxAge": 1, "name": "Dr. Frank Isaac Litvack FACC, M.D.", "age": 66, "title": "Exec. Chairman", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 120000, "fmt": "120k", "longFmt": "120,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Linda  Marb\u00e1n Ph.D.", "age": 59, "title": "Co-Founder, Pres, CEO & Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 282300, "fmt": "282.3k", "longFmt": "282,300"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1021739, "fmt": "1.02M", "longFmt": "1,021,739"}}, {"maxAge": 1, "name": "Mr. Anthony J. Bergmann M.B.A.", "age": 36, "title": "CFO & Corp. Treasurer", "yearBorn": 1986, "fiscalYear": 2022, "totalPay": {"raw": 459150, "fmt": "459.15k", "longFmt": "459,150"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 312174, "fmt": "312.17k", "longFmt": "312,174"}}, {"maxAge": 1, "name": "Ms. Karen G. Krasney", "age": 69, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1953, "fiscalYear": 2022, "totalPay": {"raw": 434532, "fmt": "434.53k", "longFmt": "434,532"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 267464, "fmt": "267.46k", "longFmt": "267,464"}}, {"maxAge": 1, "name": "Dr. Eduardo  Marb\u00e1n", "title": "Co-Founder & Chairman of Scientific Advisory Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kristi A. H. Elliott Ph.D.", "title": "Chief Science Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Catherine Lee Kelleher", "title": "Consultant", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}